PaxMedica, Inc. announced it has received an urgent request from the Ministry of Health (MOH) of Malawi, asking for emergency access to IV suramin to avert a potential humanitarian crisis brought on by dwindling supplies of drugs used routinely to save lives in that region of Africa. PaxMedica, which just last week announced that it has completed execution of its three pivotal registration/validation batches of PAX-101 (an IV form of suramin), has brought this emergency request to the attention of the U.S. Food and Drug Administration (FDA) to determine potential impact, if any, on the ongoing development program and NDA submission plans for PAX-101. PaxMedica has previously announced the completion of its recent Type B meeting with FDA in preparation for submitting an NDA for the use of PAX-101 in the treatment of the rare and fatal trypanosomal infection, Trypanosoma brucei rhodesiense, caused by the bite of a tsetse fly.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2176 USD | +0.99% |
|
-1.76% | -71.25% |
13/05 | PaxMedica, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
06/05 | PaxMedica, Inc.(NasdaqCM:PXMD) dropped from S&P TMI Index | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-71.25% | 1.69M | |
+19.41% | 45.51B | |
+38.65% | 39.36B | |
-8.62% | 38.52B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |
- Stock Market
- Equities
- PXMD Stock
- News PaxMedica, Inc.
- PaxMedica, Inc. Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness